Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of a study medicine called PF-08634404, given alone or combined with another antibody named ipilimumab, in adults with a type of liver cancer called hepatocellular carcinoma HCC that is locally advanced or has spread to other parts of the body. This study focuses on patients whose cancer cannot be removed by surgery and who have not yet received whole-body treatment for HCC. Participants will receive PF-08634404 either as a single treatment or together with ipilimumab. Both medicines will be given through intravenous IV infusions administered directly into a vein at clinical trial sites. Participants are randomly assigned to receive either the study medicine alone or in combination with the antibody, with dose levels given sequentially. During the study, participants will be monitored for safety and response to treatment, including adverse events and tumor response using standard criteria. Researchers will assess overall response rates, progression-free survival, and other health measures over approximately 24 months. Medical staff will also track blood tests, serum drug levels, and immune responses. Treatment and follow-up visits will include clinical assessments to understand the effects and side effects of these therapies.
Actively Recruiting
Researchers are evaluating a new medicine called PF-08634404 to learn how it works when combined with other cancer medicines in people with advanced solid tumors that cannot be removed by surgery or cured with standard treatments. This study focuses on participants aged 18 and older who have advanced non-small cell lung cancer NSCLC that has spread to other parts of the body. The study aims to assess the safety of PF-08634404 with other cancer medicines, observe possible side effects, and evaluate the treatments potential to help control these tumors. Participants will receive PF-08634404 combined with different anticancer agents during two main parts of the study. Part A tests PF-08634404 with Sigvotatug Vedotin, and Part B tests it with PF-08046054SGN-PDL1V. All study medicines are given through intravenous IV infusions at clinical trial sites, where trained medical staff will monitor participants during and after each visit. Throughout the study, participants will undergo regular assessments including monitoring for treatment-related side effects and serious adverse events up to 90 days after the last treatment. Researchers will also measure tumor response using imaging and clinical evaluations up to about five years. Additional tests will check laboratory abnormalities, drug levels in the blood, and immune responses to the medicine. Participants are monitored closely during visits to track safety and treatment effects.
Actively Recruiting
Researchers are evaluating radiation therapy options for men with high-risk prostate cancer in this phase III trial. The study compares a shorter course of stereotactic body radiation therapy SBRT, which delivers five high-dose treatments over two weeks, to the usual longer radiation therapy given over 4 to 9 weeks. The goal is to see if the shorter treatment is as effective in preventing cancer from returning as the standard therapy. Participants are randomly assigned to one of two groups the first group receives SBRT with five treatments over two weeks, and the second group undergoes external beam radiation therapy EBRT with 20 to 45 treatments over 4 to 9 weeks. Both groups may have bone scans, CT, MRI, or PETCT scans during screening and on study, and they may optionally provide blood and urine samples. This trial includes follow-up visits every six months for five years to monitor outcomes. During the study, participants will have various assessments including imaging and questionnaires to evaluate urinary, bowel, sexual function, fatigue, quality of life, and treatment burden. Researchers will track metastasis-free survival, failure-free survival, overall survival, adverse events, and patient-reported outcomes up to 15 years. The study aims to provide detailed information about the effectiveness and impact of the shorter radiation therapy compared to the usual treatment.
Actively Recruiting
Researchers are evaluating whether adding stereotactic ablative radiotherapy SABR to the primary tumor along with standard immunotherapy improves outcomes for patients with metastatic, unresected renal cell carcinoma RCC that cannot be surgically removed. This phase II trial compares the combination of SABR plus immunotherapy to immunotherapy alone, focusing on progression-free survival and tumor response. The study also examines safety, response rates, surgery rates, survival, and explores biomarkers and effects on tumor spread. Participants are randomly assigned in a 21 ratio to either receive immunotherapy alone or immunotherapy combined with SABR. Immunotherapy regimens include various combinations of intravenous monoclonal antibodies nivolumab, ipilimumab, pembrolizumab, avelumab and oral antiangiogenic drugs axitinib, cabozantinib, lenvatinib, administered on schedules ranging from every 2 to 6 weeks. Those in the SABR group receive radiation therapy on three separate days over 1 to 3 weeks alongside their immunotherapy. Throughout treatment, patients undergo CT or MRI scans, possible bone scans, and blood sample collections. After treatment, participants are followed every six months for five years, then annually for three more years to monitor outcomes. The study measures nephrectomy and radiographic progression-free survival up to eight years, along with secondary outcomes like response rates, overall survival, treatment-free survival, and adverse events. Regular imaging and laboratory tests track disease status and treatment effects, supporting long-term safety and efficacy assessment.